![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANAPC5 |
Gene summary for ANAPC5 |
![]() |
Gene information | Species | Human | Gene symbol | ANAPC5 | Gene ID | 51433 |
Gene name | anaphase promoting complex subunit 5 | |
Gene Alias | APC5 | |
Cytomap | 12q24.31 | |
Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q9UJX4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51433 | ANAPC5 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.19e-02 | 3.96e-01 | -0.0811 |
51433 | ANAPC5 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.66e-07 | 4.73e-01 | -0.1954 |
51433 | ANAPC5 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.43e-04 | 9.39e-01 | 0.3487 |
51433 | ANAPC5 | A015-C-203 | Human | Colorectum | FAP | 1.49e-25 | -2.75e-01 | -0.1294 |
51433 | ANAPC5 | A015-C-204 | Human | Colorectum | FAP | 3.48e-03 | -2.82e-01 | -0.0228 |
51433 | ANAPC5 | A014-C-040 | Human | Colorectum | FAP | 4.74e-03 | -3.69e-01 | -0.1184 |
51433 | ANAPC5 | A002-C-201 | Human | Colorectum | FAP | 8.30e-09 | -2.48e-01 | 0.0324 |
51433 | ANAPC5 | A002-C-203 | Human | Colorectum | FAP | 4.73e-04 | -8.24e-02 | 0.2786 |
51433 | ANAPC5 | A001-C-119 | Human | Colorectum | FAP | 4.44e-06 | -2.81e-01 | -0.1557 |
51433 | ANAPC5 | A001-C-108 | Human | Colorectum | FAP | 3.85e-12 | -1.77e-01 | -0.0272 |
51433 | ANAPC5 | A002-C-205 | Human | Colorectum | FAP | 5.65e-17 | -3.06e-01 | -0.1236 |
51433 | ANAPC5 | A001-C-104 | Human | Colorectum | FAP | 7.91e-03 | -9.38e-02 | 0.0184 |
51433 | ANAPC5 | A015-C-006 | Human | Colorectum | FAP | 3.29e-10 | -2.43e-01 | -0.0994 |
51433 | ANAPC5 | A015-C-106 | Human | Colorectum | FAP | 1.36e-09 | -1.07e-01 | -0.0511 |
51433 | ANAPC5 | A002-C-114 | Human | Colorectum | FAP | 1.58e-13 | -3.04e-01 | -0.1561 |
51433 | ANAPC5 | A015-C-104 | Human | Colorectum | FAP | 7.03e-28 | -2.87e-01 | -0.1899 |
51433 | ANAPC5 | A001-C-014 | Human | Colorectum | FAP | 9.57e-14 | -1.82e-01 | 0.0135 |
51433 | ANAPC5 | A002-C-016 | Human | Colorectum | FAP | 7.66e-23 | -2.67e-01 | 0.0521 |
51433 | ANAPC5 | A015-C-002 | Human | Colorectum | FAP | 1.71e-09 | -2.31e-01 | -0.0763 |
51433 | ANAPC5 | A001-C-203 | Human | Colorectum | FAP | 8.09e-10 | -1.29e-01 | -0.0481 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010498 | Colorectum | AD | proteasomal protein catabolic process | 174/3918 | 490/18723 | 3.18e-14 | 7.66e-12 | 174 |
GO:0043161 | Colorectum | AD | proteasome-mediated ubiquitin-dependent protein catabolic process | 141/3918 | 412/18723 | 1.77e-10 | 1.68e-08 | 141 |
GO:0000209 | Colorectum | AD | protein polyubiquitination | 78/3918 | 236/18723 | 8.71e-06 | 2.06e-04 | 78 |
GO:0033044 | Colorectum | AD | regulation of chromosome organization | 60/3918 | 187/18723 | 2.25e-04 | 2.94e-03 | 60 |
GO:0007346 | Colorectum | AD | regulation of mitotic cell cycle | 119/3918 | 457/18723 | 4.60e-03 | 3.14e-02 | 119 |
GO:0045787 | Colorectum | AD | positive regulation of cell cycle | 85/3918 | 313/18723 | 4.76e-03 | 3.22e-02 | 85 |
GO:0045842 | Colorectum | AD | positive regulation of mitotic metaphase/anaphase transition | 8/3918 | 15/18723 | 5.67e-03 | 3.64e-02 | 8 |
GO:1901970 | Colorectum | AD | positive regulation of mitotic sister chromatid separation | 8/3918 | 15/18723 | 5.67e-03 | 3.64e-02 | 8 |
GO:1905820 | Colorectum | AD | positive regulation of chromosome separation | 9/3918 | 18/18723 | 5.82e-03 | 3.67e-02 | 9 |
GO:0140014 | Colorectum | AD | mitotic nuclear division | 78/3918 | 287/18723 | 6.48e-03 | 4.05e-02 | 78 |
GO:0045931 | Colorectum | AD | positive regulation of mitotic cell cycle | 37/3918 | 121/18723 | 7.88e-03 | 4.73e-02 | 37 |
GO:00104983 | Colorectum | MSI-H | proteasomal protein catabolic process | 71/1319 | 490/18723 | 4.67e-09 | 6.03e-07 | 71 |
GO:00431613 | Colorectum | MSI-H | proteasome-mediated ubiquitin-dependent protein catabolic process | 53/1319 | 412/18723 | 1.51e-05 | 6.62e-04 | 53 |
GO:00431614 | Colorectum | FAP | proteasome-mediated ubiquitin-dependent protein catabolic process | 98/2622 | 412/18723 | 5.41e-08 | 4.20e-06 | 98 |
GO:00104984 | Colorectum | FAP | proteasomal protein catabolic process | 110/2622 | 490/18723 | 2.12e-07 | 1.26e-05 | 110 |
GO:00002093 | Colorectum | FAP | protein polyubiquitination | 59/2622 | 236/18723 | 4.53e-06 | 1.52e-04 | 59 |
GO:00330442 | Colorectum | FAP | regulation of chromosome organization | 46/2622 | 187/18723 | 7.41e-05 | 1.36e-03 | 46 |
GO:00457872 | Colorectum | FAP | positive regulation of cell cycle | 66/2622 | 313/18723 | 3.66e-04 | 4.63e-03 | 66 |
GO:00073462 | Colorectum | FAP | regulation of mitotic cell cycle | 85/2622 | 457/18723 | 3.41e-03 | 2.48e-02 | 85 |
GO:00900681 | Colorectum | FAP | positive regulation of cell cycle process | 48/2622 | 236/18723 | 4.53e-03 | 3.08e-02 | 48 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa05166 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa051661 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa04110 | Colorectum | FAP | Cell cycle | 37/1404 | 157/8465 | 1.44e-02 | 4.77e-02 | 2.90e-02 | 37 |
hsa041207 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa041101 | Colorectum | FAP | Cell cycle | 37/1404 | 157/8465 | 1.44e-02 | 4.77e-02 | 2.90e-02 | 37 |
hsa041208 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa041209 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0516639 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa041109 | Esophagus | HGIN | Cell cycle | 38/1383 | 157/8465 | 6.70e-03 | 4.37e-02 | 3.47e-02 | 38 |
hsa0465726 | Esophagus | HGIN | IL-17 signaling pathway | 25/1383 | 94/8465 | 7.52e-03 | 4.63e-02 | 3.68e-02 | 25 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa05166114 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa0411016 | Esophagus | HGIN | Cell cycle | 38/1383 | 157/8465 | 6.70e-03 | 4.37e-02 | 3.47e-02 | 38 |
hsa04657113 | Esophagus | HGIN | IL-17 signaling pathway | 25/1383 | 94/8465 | 7.52e-03 | 4.63e-02 | 3.68e-02 | 25 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANAPC5 | SNV | Missense_Mutation | novel | c.688N>T | p.Ala230Ser | p.A230S | Q9UJX4 | protein_coding | deleterious(0.01) | probably_damaging(0.955) | TCGA-CN-A63W-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | vectibix | CR |
ANAPC5 | SNV | Missense_Mutation | c.1259N>C | p.Ile420Thr | p.I420T | Q9UJX4 | protein_coding | tolerated(1) | benign(0.159) | TCGA-G9-6339-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | PD | |
ANAPC5 | SNV | Missense_Mutation | c.2079N>A | p.Asn693Lys | p.N693K | Q9UJX4 | protein_coding | tolerated(0.8) | benign(0.053) | TCGA-G9-6356-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD | |
ANAPC5 | SNV | Missense_Mutation | c.2044A>C | p.Lys682Gln | p.K682Q | Q9UJX4 | protein_coding | tolerated(0.8) | benign(0.001) | TCGA-J9-A52C-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD | |
ANAPC5 | SNV | Missense_Mutation | c.1310N>C | p.Met437Thr | p.M437T | Q9UJX4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-BR-4368-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ANAPC5 | SNV | Missense_Mutation | rs772518488 | c.1519T>C | p.Trp507Arg | p.W507R | Q9UJX4 | protein_coding | deleterious(0) | possibly_damaging(0.75) | TCGA-BR-8078-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC5 | SNV | Missense_Mutation | rs369898477 | c.1799N>T | p.Ala600Val | p.A600V | Q9UJX4 | protein_coding | tolerated(0.1) | probably_damaging(0.943) | TCGA-CG-5726-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ANAPC5 | SNV | Missense_Mutation | novel | c.1115N>T | p.Gly372Val | p.G372V | Q9UJX4 | protein_coding | tolerated(0.13) | benign(0.115) | TCGA-FP-8631-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
ANAPC5 | SNV | Missense_Mutation | novel | c.1071C>A | p.Ser357Arg | p.S357R | Q9UJX4 | protein_coding | tolerated(0.21) | possibly_damaging(0.852) | TCGA-VQ-A8PB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | CR |
ANAPC5 | SNV | Missense_Mutation | c.1165N>A | p.Ala389Thr | p.A389T | Q9UJX4 | protein_coding | deleterious(0) | possibly_damaging(0.82) | TCGA-DJ-A13O-01 | Thyroid | thyroid carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |